U.S. markets open in 7 hours 39 minutes

Tetra Bio-Pharma Inc. (TBP.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
0.4200-0.0550 (-11.58%)
At close: 4:00PM EDT
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.4750
Open0.4750
Bid0.4150 x N/A
Ask0.4200 x N/A
Day's Range0.4100 - 0.5000
52 Week Range0.1350 - 0.5300
Volume8,166,023
Avg. Volume3,624,638
Market Cap150.557M
Beta (5Y Monthly)1.97
PE Ratio (TTM)N/A
EPS (TTM)-0.1130
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Tetra Bio-Pharma Signs a Definitive Distribution Agreement with DanCann Pharma to Monetize Its Dronabinol and Botanical Product Portfolios
      ACCESSWIRE

      Tetra Bio-Pharma Signs a Definitive Distribution Agreement with DanCann Pharma to Monetize Its Dronabinol and Botanical Product Portfolios

      This Definitive Agreement is expected to generate an excess of $47,5M CAD in revenue for TetraOTTAWA, ON / ACCESSWIRE / May 5, 2021 /Tetra Bio-Pharma Inc. ("Tetra" or the "Company")(TSX:TBP)(OTCQB:TBPMF)(FSE:JAM1), a leader in cannabinoid-derived drug discovery and development announced today the signing of a Definitive Agreement with DanCann Pharma A/S (SS: DANCAN) for the exclusive distribution of Reduvo™ Adversa®, QIXLEEF™ and ENJOUCA™ in Denmark, Norway, Sweden, Finland, and Germany.

    • Tetra Bio-Pharma Re-activates Veterinary Clinical Study in Companion Animals
      ACCESSWIRE

      Tetra Bio-Pharma Re-activates Veterinary Clinical Study in Companion Animals

      A first of its kind synthetic cannabinoid medication to manage eye pain in the veterinary settingOTTAWA, ON / ACCESSWIRE / May 4, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company")(TSX:TBP)(OTCQB:TBPMF)(FRA:JAM1), a biopharmaceutical pioneer in immunomodulator drug discovery and development is pleased to announce that it has received authorization from the Veterinary Drugs Directorate of Health Canada for a one year extension to continue the clinical trial evaluating the safety, tolerability and potential efficacy of its veterinary ophthalmic drug, PPP-003v, in the treatment of indolent corneal ulcers in companion animals.

    • Tetra Bio-Pharma Granted a Drug Establishment License to Distribute REDUVO Soft Gel Capsules in Canada
      ACCESSWIRE

      Tetra Bio-Pharma Granted a Drug Establishment License to Distribute REDUVO Soft Gel Capsules in Canada

      The addressable market in Canada is estimated to be $80M CDN by 2022.Tetra also applies for a Health Canada Cannabis Drug LicenseOTTAWA, ON / ACCESSWIRE / May 3, 2021 / Tetra Bio-Pharma Inc.